BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

694 related articles for article (PubMed ID: 32483411)

  • 1. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
    Xu H; Wang H; Zhao W; Fu S; Li Y; Ni W; Xin Y; Li W; Yang C; Bai Y; Zhan M; Lu L
    Theranostics; 2020; 10(13):5671-5686. PubMed ID: 32483411
    [No Abstract]   [Full Text] [Related]  

  • 2. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.
    Chen M; Wei L; Law CT; Tsang FH; Shen J; Cheng CL; Tsang LH; Ho DW; Chiu DK; Lee JM; Wong CC; Ng IO; Wong CM
    Hepatology; 2018 Jun; 67(6):2254-2270. PubMed ID: 29171881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
    Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
    Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
    Du Y; Hou G; Zhang H; Dou J; He J; Guo Y; Li L; Chen R; Wang Y; Deng R; Huang J; Jiang B; Xu M; Cheng J; Chen GQ; Zhao X; Yu J
    Nucleic Acids Res; 2018 Jun; 46(10):5195-5208. PubMed ID: 29506078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway.
    Qiao K; Liu Y; Xu Z; Zhang H; Zhang H; Zhang C; Chang Z; Lu X; Li Z; Luo C; Liu Y; Yang C; Sun T
    Angiogenesis; 2021 Feb; 24(1):83-96. PubMed ID: 32920668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA m
    Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
    EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma.
    Liu B; Cao J; Wu B; Hao K; Wang X; Chen X; Shen Z
    Cell Commun Signal; 2023 May; 21(1):121. PubMed ID: 37231451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
    Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
    Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced N6-Methyladenosine Mediated by METTL3 Acetylation Promotes MTF1 Expression and Hepatocellular Carcinoma Cell Growth.
    Yang Y; Qian Cai Q; Sheng Fu L; Wei Dong Y; Fan F; Zhong Wu X
    Chem Biodivers; 2022 Nov; 19(11):e202200333. PubMed ID: 36149370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
    Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
    Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
    Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
    Liu X; Qin J; Gao T; Li C; Chen X; Zeng K; Xu M; He B; Pan B; Xu X; Pan Y; Sun H; Xu T; Wang S
    Aging (Albany NY); 2020 Nov; 12(21):21638-21659. PubMed ID: 33159022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis.
    Ouyang P; Li K; Xu W; Chen C; Shi Y; Tian Y; Gong J; Bao Z
    J Exp Clin Cancer Res; 2024 Apr; 43(1):111. PubMed ID: 38605400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. METTL3-mediated m6A methylation of ASPM drives hepatocellular carcinoma cells growth and metastasis.
    Wang A; Chen X; Li D; Yang L; Jiang J
    J Clin Lab Anal; 2021 Sep; 35(9):e23931. PubMed ID: 34398984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription factor RELA promotes hepatocellular carcinoma progression by promoting the transcription of m6A modulator METTL3.
    Wu J; Wang W; Zheng Y; Deng W; Liu J
    Pathol Res Pract; 2024 Mar; 255():155168. PubMed ID: 38367599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.
    Pan J; Liu F; Xiao X; Xu R; Dai L; Zhu M; Xu H; Xu Y; Zhao A; Zhou W; Dang Y; Ji G
    J Exp Clin Cancer Res; 2022 Jan; 41(1):19. PubMed ID: 35012593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
    Liu GM; Zeng HD; Zhang CY; Xu JW
    Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. METTL3 facilitates tumor progression via an m
    Li T; Hu PS; Zuo Z; Lin JF; Li X; Wu QN; Chen ZH; Zeng ZL; Wang F; Zheng J; Chen D; Li B; Kang TB; Xie D; Lin D; Ju HQ; Xu RH
    Mol Cancer; 2019 Jun; 18(1):112. PubMed ID: 31230592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.